Expect to produce globally up to 50 million doses in 2020, up to 1.3 billion doses by the end of 2021; ready to distribute within hours after authorization.
To support CStone’s development of sugemalimab, a potential best-in-class PD-L1 antibody being developed for high-incidence cancer indications in China.